These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22927449)

  • 1. Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma.
    Pasternak AO; de Bruin M; Jurriaans S; Bakker M; Berkhout B; Prins JM; Lukashov VV
    J Infect Dis; 2012 Nov; 206(9):1443-52. PubMed ID: 22927449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
    Gianella S; von Wyl V; Fischer M; Niederoest B; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
    Antivir Ther; 2011; 16(4):535-45. PubMed ID: 21685541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.
    Murphy DA; Belzer M; Durako SJ; Sarr M; Wilson CM; Muenz LR;
    Arch Pediatr Adolesc Med; 2005 Aug; 159(8):764-70. PubMed ID: 16061785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
    Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
    J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; Carrieri MP; Laurent C; Kouanfack C; Protopopescu C; Blanche J; Cohen J; Laborde-Balen G; Aghokeng AF; Spire B; Moatti JP; Delaporte E; Boyer S;
    Antivir Ther; 2013; 18(1):29-37. PubMed ID: 23358393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
    Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
    HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications.
    Glikman D; Walsh L; Valkenburg J; Mangat PD; Marcinak JF
    Pediatrics; 2007 May; 119(5):e1142-8. PubMed ID: 17452493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
    Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
    N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No evidence of an association between transient HIV viremia ("Blips") and lower adherence to the antiretroviral medication regimen.
    Miller LG; Golin CE; Liu H; Hays RD; Hua J; Wenger NS; Kaplan AH
    J Infect Dis; 2004 Apr; 189(8):1487-96. PubMed ID: 15073687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.